INCY News and Press, Incyte Corporation From 05/23/20

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

T he MAA seeks approval of tafasitamab in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma MUNICH, GERMANY / ACCESSWIRE / May 20, 2020 / MorphoSys AG (FSE:MOR) Prime Standard Segment; MDAX & TecDAX;...

- The MAA seeks approval of tafasitamab in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma Incyte (NASDAQ:INCY) and MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) today announced...

After four abstracts were released highlighting the latest data on its lead drug candidate, imetelstat, shares of Geron   (NASDAQ: GERN) were trading 23.4% higher as of 1:21 p.m. EST on Friday. Previously, Geron's prospects were dealt a significant blow when former imetelstat co-d...

Incyte (Nasdaq: INCY) today announced that multiple abstracts highlighting data from clinical trials of medicines that are being developed in-house and through partnerships with Novartis, MorphoSys and Takeda will be presented at the upcoming 2020 American Society of Clinical Oncology Virtual...

MorphoSys AG ( MOR +2.5% ) and collaboration partner Incyte ( INCY -2.2% ) announce two-year follow-up data from a Phase 2 clinical trial, L-MIND , evaluating the combination of tafasitamab and lenalidomide (branded as Revlimid by Celgene) in patients with relapsed/refractory diffuse ...

Biotech Pulse Source: COVID-19 image by Getty Images; edits by PrudentBiotech.com It has taken a pandemic for biotechs to take flight towards their all-time high. One of the first industry groups to recover from the virus-related selloff and be neutral for the year, biotech indexes hav...

Incyte ( INCY -1.9% ) announces that the FDA has approved exclusive licensee Novartis' ( NVS +1.2% ) Tabrecta (capmatinib) for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to MET exon 14 skipping (METex14) as...

- Tabrecta is the first and only U.S. Food and Drug Administration (FDA)-approved treatment for adult patients with metastatic non-small cell lung cancer (NSCLC) with a mutation that leads to MET exon 14 skipping (METex14) - Tabrecta is the fourth molecule discovered by Incyte scientis...

Image source: The Motley Fool. Incyte Corp   (NASDAQ: INCY) Q1 2020 Earnings Call May 5, 2020 , 8:00 a.m. ET Operator Continue reading